# C16020 (NCT02046070)

> Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: ixazomib plus cyclophosphamide plus dexamethasone
- Indication: newly diagnosed or relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02046070
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Millennium Pharmaceuticals, Inc.
- Conditions: Multiple Myeloma
- Interventions: Cyclophosphamide; Ixazomib; Dexamethasone
- Enrollment: 148
- Primary outcome: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants
- Primary outcome: Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants

## Indexed commentary on C16020 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=c16020-nct02046070